Bio Rad Laboratories Inc (NYSE:BIO)
| 581.55 Delayed Data As of Oct 23 |  +2.51 / +0.43%Today’s Change | 309.38 Today|||52-Week Range 586.20 | +57.16% Year-to-Date |
Latest BIO News | Press Releases
| Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards? Oct 23 / Zacks.com - Paid Partner Content | Bio-Rad (BIO) Hits a New 52-Week High: What's Driving It? Oct 12 / Zacks.com - Paid Partner Content |
| Bio-Rad Laboratories (BIO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Oct 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 579.04 |
| Today’s open | 559.34 |
| Day’s range | 574.46 - 584.51 |
| Volume | 99,642 |
| Average volume (3 months) | 219,649 |
| Market cap | $13.7B |
Data as of 4:00pm ET, 10/23/2020
Growth & Valuation
| Earnings growth (last year) | +380.91% |
| Earnings growth (this year) | +12.23% |
| Earnings growth (next 5 years) | +4.00% |
| Revenue growth (last year) | +0.97% |
| P/E ratio | 9.0 |
| Price/Sales | 4.83 |
| Price/Book | 2.89 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| PKIPerkinElmer Inc | -0.71 | -0.57% |
| WATWaters Corp | -0.16 | -0.07% |
| QGENQiagen NV | -0.73 | -1.45% |
| BRKRBruker Corp | -0.80 | -1.85% |
Data as of 4:00pm ET, 10/23/2020
Financials
| Next reporting date | October 30, 2020 |
| EPS forecast (this quarter) | $1.80 |
| Annual revenue (last year) | $2.3B |
| Annual profit (last year) | $1.8B |
| Net profit margin | 76.08% |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters Hercules, California |
Forecasts
